| Recruiting | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Vers NCT07124078 | Incyte Corporation | Phase 2 |
| Not Yet Recruiting | Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease NCT07535008 | Fred Hutchinson Cancer Center | N/A |
| Not Yet Recruiting | A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versu NCT07135973 | Sanofi | Phase 4 |
| Recruiting | Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chroni NCT07127926 | M.D. Anderson Cancer Center | — |
| Recruiting | A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease NCT07138196 | Qurient Co., Ltd. | Phase 1 |
| Recruiting | A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) NCT07116031 | Sanofi | Phase 2 |
| Recruiting | Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD NCT06233110 | Stefanie Sarantopoulos, MD, PhD. | Phase 1 |
| Recruiting | Axatilimab for Sclerotic Chronic Graft-versus-Host Disease NCT07011810 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy NCT07012304 | Yujun DONG | Phase 1 / Phase 2 |
| Recruiting | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD NCT06843408 | Incyte Corporation | Phase 1 / Phase 2 |
| Withdrawn | Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Na NCT05567406 | Kadmon, a Sanofi Company | Phase 2 |
| Active Not Recruiting | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Di NCT06821542 | Incyte Corporation | Phase 3 |
| Recruiting | Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease NCT06663722 | University of Miami | Phase 2 |
| Terminated | Upfront Ruxolitinib for Chronic Graft-vs-host Disease NCT06695507 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Recruiting | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease NCT06585774 | Incyte Corporation | Phase 3 |
| Recruiting | Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Trans NCT06271616 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Digital Health Intervention to Promote Quality of Life in Adults With Chronic Graft Versus Host Disease NCT06688942 | University of Miami | N/A |
| Active Not Recruiting | A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents NCT06616415 | Sanofi | Phase 4 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With NCT06388564 | Incyte Corporation | Phase 2 |
| Active Not Recruiting | Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease NCT06458127 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participa NCT06263478 | Incyte Biosciences Japan GK | Phase 3 |
| Recruiting | BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) NCT05922761 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD) NCT06247150 | University Hospital, Bordeaux | N/A |
| Recruiting | A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease NCT06300320 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Suspended | Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With NCT05993611 | City of Hope Medical Center | Phase 1 |
| Recruiting | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease NCT06046248 | Northside Hospital, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 NCT06143891 | Sanofi | Phase 3 |
| Recruiting | Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease NCT05996627 | Fred Hutchinson Cancer Center | Phase 2 |
| Unknown | Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201) NCT05692713 | University of British Columbia | — |
| Active Not Recruiting | Psychosocial Mobile App for Chronic Graft-Versus-Host Disease NCT05690971 | Massachusetts General Hospital | N/A |
| Unknown | The Association of Microbiota Composition With cGVHD After Allo-HSCT NCT05355675 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial NCT05236062 | Dana-Farber Cancer Institute | N/A |
| Unknown | Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease NCT05348096 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Completed | Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 NCT05305989 | Kadmon, a Sanofi Company | Phase 2 |
| Completed | Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease NCT05121142 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Active Not Recruiting | A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease NCT04944043 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib NCT04640025 | Incyte Corporation | Phase 2 |
| Active Not Recruiting | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) NCT04710576 | Syndax Pharmaceuticals | Phase 2 |
| Terminated | Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD NCT04446182 | University of Utah | Phase 2 |
| Unknown | MSC for Treatment of cGVHD After Allo-HSCT NCT04692376 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Completed | Dexamethasone Solution and Dexamethasone in Mucolox™ NCT04540133 | University of California, San Francisco | Phase 2 |
| Unknown | Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study NCT04372524 | University of British Columbia | — |
| Active Not Recruiting | ATG Plus PTCy vs ATG for CGVHD Prophylaxis NCT04202835 | McMaster University | Phase 2 |
| Recruiting | Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study NCT04431479 | Fred Hutchinson Cancer Center | — |
| Terminated | A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) NCT04200365 | SCRI Development Innovations, LLC | Phase 2 |
| Active Not Recruiting | Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease NCT04212416 | City of Hope Medical Center | Phase 1 |
| Terminated | Anlotinib Treatment in Steroid Depenent/Refractory cGVHD NCT04232397 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Terminated | Glasdegib for Chronic Graft-Versus-Host Disease NCT04111497 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT NCT04716075 | Polish Lymphoma Research Group | Phase 2 |
| Terminated | Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT NCT03689894 | Dartmouth-Hitchcock Medical Center | Phase 1 / Phase 2 |
| Terminated | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease NCT03584516 | Incyte Corporation | Phase 2 / Phase 3 |
| Completed | Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Dise NCT03790332 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD NCT03604692 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy NCT03640481 | Kadmon, a Sanofi Company | Phase 2 |
| Terminated | Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies NCT03557749 | Masonic Cancer Center, University of Minnesota | — |
| Completed | Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Di NCT03483675 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Prospective Observational Study for Evaluating CGVHD NCT02991846 | Gruppo Italiano Trapianto di Midollo Osseo | — |
| Unknown | A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT NCT03190733 | Zhujiang Hospital | Phase 4 |
| Completed | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants W NCT02959944 | Pharmacyclics LLC. | Phase 3 |
| Completed | Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Gra NCT03007238 | City of Hope Medical Center | Phase 2 |
| Completed | Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide NCT02966301 | Medsenic | Phase 2 |
| Completed | Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic NCT02759731 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod NCT02461134 | Actelion | Phase 2 |
| Unknown | Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Dise NCT04189432 | SCM Lifescience Co., LTD. | Phase 2 |
| Unknown | Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis NCT03839069 | National Taiwan University Hospital | N/A |
| Completed | Multiple Donor Treg DLI for Severe Refractory Chronic GVHD NCT02749084 | Mario Arpinati | Phase 1 / Phase 2 |
| Terminated | Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy NCT02701634 | Gilead Sciences | Phase 2 |
| Active Not Recruiting | Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogen NCT02669251 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD NCT02918188 | Navy General Hospital, Beijing | Phase 2 |
| Completed | Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease NCT02513498 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease NCT02491359 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease NCT02337517 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease NCT02611180 | Washington University School of Medicine | — |
| Completed | A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractor NCT02340676 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | BMT Autologous MSCs for GvHD NCT02359929 | Emory University | Phase 1 |
| Unknown | Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH) NCT02352064 | University Hospital, Caen | N/A |
| Unknown | Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells NCT02291770 | Guangdong Provincial People's Hospital | Phase 3 |
| Terminated | An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Ho NCT02123966 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) NCT01954979 | Beth Israel Deaconess Medical Center | Phase 1 |
| Completed | Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD NCT02411474 | Yonsei University | — |
| Completed | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients( NCT02040623 | Rigel Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disea NCT01937468 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | A Long-term Extension Study of PCI-32765 (Ibrutinib) NCT01804686 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children NCT01898377 | Seoul National University Hospital | Phase 2 |
| Terminated | Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) NCT01903473 | University of Liege | Phase 2 |
| Completed | Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolim NCT01862965 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Completed | Microvascular and Fibrosis Imaging Study NCT01758250 | Duke University | — |
| Unknown | Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease NCT01765660 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Completed | Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease NCT01680965 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Dise NCT01526850 | Chinese Academy of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) NCT01380535 | Mallinckrodt | EARLY_Phase 1 |
| Completed | Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD NCT01810718 | Gruppo Italiano Trapianto di Midollo Osseo | Phase 1 |
| Active Not Recruiting | Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease NCT01366092 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) NCT01161628 | Northside Hospital, Inc. | Phase 2 |
| Terminated | Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGv NCT01964625 | University of Rochester | N/A |
| Terminated | Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease NCT01226420 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) NCT01158105 | Baylor Research Institute | Phase 2 |
| Completed | Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem C NCT01956903 | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | Phase 1 / Phase 2 |
| Completed | Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease NCT01036958 | National Cancer Institute (NCI) | — |
| Completed | Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease NCT00815919 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Montelukast to Treat Bronchiolitis Obliterans NCT00656058 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Improving Outcomes Assessment in Chronic GVHD NCT00637689 | Fred Hutchinson Cancer Center | — |
| Unknown | Treatment of Chronic GVHD of Liver or Lungs by ECP NCT00271869 | Medical University of Vienna | Phase 2 |
| Withdrawn | A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease NCT01028313 | SCRI Development Innovations, LLC | Phase 2 |